Proteome Regulatory News (PRM)

PRESS RELEASE

CK1d inhibitors reduce Alzheimer's tau phosphorylation

5 November 2015 - Cobham, UK

From the 8th Clinical Trials on Alzheimer's Disease (CTAD) in Barcelona, Proteome Sciences is pleased to announce that a recently completed study testing its proprietary inhibitors of casein kinase 1 delta (CK1d) reduced the level of tau phosphorylation in a second in vivo model of Alzheimer's disease (AD) tauopathy. Compounds were given orally for five days and the level of tau phosphorylation in the brain cortex was reduced compared to the control group. These results confirmed and are consistent with the previous in vivo study in a different AD model that revealed reduced tau phosphorylation when the compounds were given daily for 8 weeks.

Commenting on the results of the study, Dr. Ian Pike, Chief Operating Officer at Proteome Sciences said:

 "We now have compelling evidence that both acute and chronic dosing of our CK1d inhibitors is reducing levels of phosphorylated tau in the brains of two different models of AD. Surprisingly, the effect of acute dosing on phosphorylated tau was nearly as potent as the chronic administration.

Using our SysQuant global phosphoproteomic workflow we also saw that acute dosing resulted in some early changes in many of the downstream pathways we have previously identified that are affected by tau toxicity in human AD and were responsive to chronic CK1d inhibitor dosing.

The data from the two in-vivo studies provides excellent support for the beneficial effects of our compounds PS 110 and PS 278-05 and their translation to human disease and adds further substance to our partnering discussions."

ENDS

For further information please contact:

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.